https://www.news-medical.net/news/20241027/Phase-3-trial-assesses-clazakizumab-in-kidney-transplant-recipients-with-caAMR.aspx
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a...
kidney transplantphasetrialassessesclazakizumab